How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cell Transplantatio Therapy Market
- By Cell Type: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Induced Pluripotent Stem Cells, Cardiac Stem Cells
- By Application: Oncology, Neurological Disorders, Cardiovascular Diseases, Orthopedic Disorders, Autoimmune Diseases
- By Source of Cells: Autologous Cell Transplantation, Allogeneic Cell Transplantation, Xenogeneic Cell Transplantation
- By Therapy Technique: Ex Vivo Cell Expansion, Direct Cell Injection, Scaffold-Based Cell Delivery, Gene-Modified Cell Transplantation
- By End User: Hospitals, Specialty Clinics, Research Institutes, Contract Research Organizations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hematopoietic Stem Cells leads By Cell Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Cell Transplantatio Therapy Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fate Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Mesoblast Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Osiris Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Inc. (a subsidiary of Smith & Nephew)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Athersys Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pluristem Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →TiGenix NV (a subsidiary of Takeda Pharmaceutical Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Vericel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cytori Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Caladrius Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cellular Biomedicine Group Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Kiadis Pharma (a Sanofi company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Gamida Cell Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sangamo Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Celyad Oncology SA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Anterogen Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hematopoietic Stem Cells45.1
- Mesenchymal Stem Cells18.6
- Neural Stem Cells19.2
- Induced Pluripotent Stem Cells7.7
- Cardiac Stem Cells9.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fate Therapeutics Inc.12.8
- Mesoblast Limited14.1
- Osiris Therapeutics14.2
- Inc. (a subsidiary of Smith & Nephew)18.0
- Athersys Inc.5.7
- Pluristem Therapeutics Inc.7.3
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe23.1
- Asia Pacific22.6
- Latin America11.4
- Middle East and Africa10.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | 73 | 93 | 91 | 86 | 91 | 84 | 86 |
| Mesoblast Limited | 89 | 87 | 84 | 83 | 89 | 90 | 87 |
| Osiris Therapeutics | 80 | 83 | 77 | 72 | 73 | 75 | 77 |
| Inc. (a subsidiary of Smith & Nephew) | 72 | 65 | 66 | 81 | 81 | 64 | 72 |
| Athersys Inc. | 66 | 71 | 64 | 64 | 55 | 58 | 63 |
| Pluristem Therapeutics Inc. | 61 | 61 | 60 | 47 | 46 | 66 | 57 |
| TiGenix NV (a subsidiary of Takeda Pharmaceutical Company) | 59 | 52 | 64 | 49 | 43 | 62 | 55 |
| Vericel Corporation | 49 | 47 | 42 | 47 | 45 | 39 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fate Therapeutics Inc.
- Mesoblast Limited
- Osiris Therapeutics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Mesoblast Limited | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Osiris Therapeutics | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Inc. (a subsidiary of Smith & Nephew) | − | ◐ | ◐ | ✓ | ✓ | ◐ |
| Athersys Inc. | ◐ | − | − | ◐ | − | − |
| Pluristem Therapeutics Inc. | ◐ | ◐ | ◐ | − | − | ◐ |
| TiGenix NV (a subsidiary of Takeda Pharmaceutical Company) | − | − | ◐ | − | ◐ | − |
| Vericel Corporation | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Cell Type in North America, then scale across Cell Transplantatio Therapy Market — a $409M beachhead inside a $5.58B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Hematopoietic Stem Cells
Best fit — highest urgency & budget in Cell Type.
Mesenchymal Stem Cells
Strong fit — clear ROI and a fast path to value.
Neural Stem Cells
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Cell Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Source of Cells
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Cell Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell Transplantatio Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Cell Transplantatio Therapy Market is a durable-growth opportunity — $7.20B by 2033, compounding at 7.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.6% CAGR
Demand compounds through 2033, outpacing GDP across Cell Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Cell Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Cell Transplantatio Therapy Market — a $10.3B market by 2033. Plan: grow share from 8.4% to 15.3%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 15.3% | On track |
| Revenue | $925M | $1.58B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.6% | 44.2% | Behind |
| Customer retention | 85.0% | 94.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Cell Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Cell Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $187M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Cell Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAt risk
Sales deck · value proposition
Win the Cell Transplantatio Therapy Market conversation — a $9.43B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Cell Type
Goal Grow share in Cell Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell Transplantatio Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Cell Transplantatio Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cell Transfection Reagent Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCell Therapy Technologies Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCell Therapy Regenerative Medicine Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCell Therapy Monitoring Kits Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportCell Therapy Manufacturing Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCell Therapy Isolators Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportCell Therapy Growth Factors Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCell Therapy CMO Market
Cell Therapy CMO Market is valued at USD 8.2 Billion in 2025 and is expected to reach USD 18.3 …
$8.2B market · 2025 base year
View reportCell Therapy CDMO Services Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCell Therapy CDMO Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCell Therapy Bioprocessing Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportCell Therapy and Acellular Therapy Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy